Insmed Lifts 2026 BRINSUPRI Guidance to $1.35–1.40B After $524.4M Q3
INSM sits 23% above its 52-week low of $90.39 on elevated volume (3.9× avg).
Summary
Insmed's Q3 revenue of $524.4M rose 268% year over year, with BRINSUPRI at $400.1M globally (up 29% sequentially) and ARIKAYCE at $124.4M. The net loss was $100.32M. The new information is the raised 2026 outlook: BRINSUPRI now $1.35–1.40B and ARIKAYCE $460–470M, following the August raise. The company held about $1.1B in cash, cash equivalents and marketable securities at September 30, 2026. On the pipeline, PALM-ILD Phase 3 is more than 35% enrolled with enrollment due H1 2028; PALM-PAH dosed its first patient in July 2026, PALM-PPF began in September 2026, and an IPF Phase 3 is planned for H1 2027. The FDA priority review for the ARIKAYCE label expansion carries a target action date in January 2027.
At the time of this announcement, INSM was trading at $110.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.4B. The 52-week trading range was $90.39 to $212.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.